Skip to main content
. 2020 Aug 31;25(4):356–365. doi: 10.1111/jns.12408

TABLE 1.

Demographics and disease characteristics patients at baseline ‐ TTS

Ig‐naïveN = 23 Ig‐pre‐treatedN = 20 OverallN = 43
Age (years)
Mean ± SD 48.7 ± 15.8 55.8 ± 15.0 52.0 ± 15.7
Median 48.0 59.0 50.0
Min‐max 21‐78 24‐79 21‐79
Gender, N (%)
Male 12 (52.2%) 12 (60.0%) 24 (55.8%)
Female 11 (47.8%) 8 (40.0%) 19 (44.2%)
Body mass index (kg/m2)
Mean ± SD 25.6 ± 4.8 24.3 ± 4.4 25.0 ± 4.6
Median 25.4 24.6 25.1
Min‐max 18.2‐40.0 14.3‐31.9 14.3‐40.0
Diagnostic categories of CIDP, N (%) a
Definite 20 (87%) 20 (100%) 40 (93%)
Probable 3 (13%) 0 3 (7%)
Time since first symptoms (years)
Mean ± SD 6.7 ± 7.4 6.7 ± 5.6 6.7 ± 6.5
Median 3.6 3.4 3.4
Min‐max 0.4‐28.6 0.4‐17.3 0.4‐28.6
Time since diagnosis (years)
Mean ± SD 2.7 ± 6.0 5.0 ± 5.5 3.8 ± 5.8
Median 0.2 2.4 1.2
Min‐max 0.0 b ‐23.3 0.0 c ‐16.8 0.0 c ‐23.3
Total adjusted INCAT disability score
Mean ± SD 2.7 ± 1.3 3.3 ± 1.8 3.0 ± 1.5
Median 2.0 2.5 2.0
Min‐max 2‐6 2‐8 2‐8

Note: Range of total adjusted INCAT disability score: 0 (normal) to 9 (maximum disability). Range of adjusted INCAT disability arms score: 0 to 4. Range of adjusted INCAT disability legs score: 0 to 5.

Abbreviations: CIDP, chronic inflammatory demyelinating polyneuropathy; INCAT, inflammatory neuropathy cause and treatment; N, number of patients; TTS, total treated set.

a

CIDP diagnosis was considered as definite or probable according to the EFNS/PNS guidelines 2010 clinical and neurophysiological criteria.

b

The minimal values of 0.0 years correspond to periods of time < 18 days (since Min values were documented in year with only one decimal).

c

In the Ig‐pre‐treated subgroup, one patient had been pre‐treated 5 months before by Ig for CIDP symptoms, but the diagnosis was confirmed only 4 days before the inclusion in the study explaining the value 0.0 year for time since diagnosis.